Lunai Bioworks Inc.
For the period ended Jun 30, 2025. Filed Sep 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 29, 2025
LNAI$0.16-30.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at June 30, 2025 and 2024
CONSOLIDATED BALANCE SHEETS
| June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash | $92,700 | $220,467 |
| Insurance receivable | — | 1,108,247 |
| Investment in equity securities | 387,851 | — |
| Prepaids and other assets | 566,081 | 668,929 |
| Total Current Assets | 1,046,632 | 1,997,643 |
| Property and equipment, net | 367,843 | 482,121 |
| OTHER ASSETS | ||
| Definite life intangible assets, net | 14,994 | 30,043 |
| Software platform | 143,000 | — |
| Trademarks | 8,000 | — |
| Goodwill | 5,963,000 | 159,330,161 |
| Deposits and other assets | — | 19,849 |
| Operating lease right-of-use assets | 687,371 | 1,269,633 |
| Total Other Assets | 6,816,365 | 160,649,686 |
| TOTAL ASSETS | $8,230,840 | $163,129,450 |
| LIABILITIES | ||
| CURRENT LIABILITIES: | ||
| Accounts payable – trade | $12,555,839 | $9,448,683 |
| Accrued expenses | 5,843,069 | 5,311,324 |
| Other current liabilities | 378,282 | 295,361 |
| Contingent consideration liability | 630,000 | 12,310,000 |
| Convertible notes payable | 245,000 | 245,000 |
| Current portion of operating lease liabilities | 313,047 | 493,553 |
| Notes payable | 3,580,525 | — |
| Notes payable – related parties, net | 5,610,372 | 2,205,996 |
| Total Current Liabilities | 29,156,134 | 30,309,917 |
| NON-CURRENT LIABILITIES: | ||
| Operating lease liabilities, net of current portion | 424,547 | 842,389 |
| Total Non-Current Liabilities | 424,547 | 842,389 |
| Total Liabilities | 29,580,681 | 31,152,306 |
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, par value $0.0001, 350,000,000 shares authorized, 177,392,907 shares issued and outstanding at June 30, 2025; 158,452,644 shares issued and outstanding at June 30, 2024 | 17,741 | 15,847 |
| Additional paid-in capital | 478,280,146 | 464,587,224 |
| Accumulated deficit | (510,462,570) | (332,455,081) |
| Accumulated other comprehensive (loss) | 10,814,842 | (170,846) |
| Total Stockholders’ Equity (Deficit) | (21,349,841) | 131,977,144 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $8,230,840 | $163,129,450 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.